Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2810725

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest expense
0 EUR
0 EUR
Cash flows from (used in) operations before changes in working capital
4 236 EUR
3 456 EUR
Increase (decrease) in working capital
538,000 EUR
97,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.